Literature DB >> 19587164

Sclerostin in mineralized matrices and van Buchem disease.

R L van Bezooijen1, A L Bronckers, R A Gortzak, P C W Hogendoorn, L van der Wee-Pals, W Balemans, H J Oostenbroek, W Van Hul, H Hamersma, F G Dikkers, N A T Hamdy, S E Papapoulos, C W G M Löwik.   

Abstract

Sclerostin is an inhibitor of bone formation expressed by osteocytes. We hypothesized that sclerostin is expressed by cells of the same origin and also embedded within mineralized matrices. In this study, we analyzed (a) sclerostin expression using immunohistochemistry, (b) whether the genomic defect in individuals with van Buchem disease (VBD) was associated with the absence of sclerostin expression, and (c) whether this was associated with hypercementosis. Sclerostin was expressed by cementocytes in mouse and human teeth and by mineralized hypertrophic chondrocytes in the human growth plate. In individuals with VBD, sclerostin expression was absent or strongly decreased in osteocytes and cementocytes. This was associated with increased bone formation, but no overt changes in cementum thickness. In conclusion, sclerostin is expressed by all 3 terminally differentiated cell types embedded within mineralized matrices: osteocytes, cementocytes, and hypertrophic chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587164     DOI: 10.1177/0022034509338340

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  47 in total

Review 1.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 2.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

3.  Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6.

Authors:  Ning Zhao; Francisco H Nociti; Peipei Duan; Matthew Prideaux; Hong Zhao; Brian L Foster; Martha J Somerman; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2015-09-23       Impact factor: 6.741

4.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

Review 5.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

6.  Pax6 expressed in osteocytes inhibits canonical Wnt signaling.

Authors:  Ajita Jami; Jogeswar Gadi; Min Jung Lee; Eun Jin Kim; Mi Jeong Lee; Han-Sung Jung; Hong-Hee Kim; Sung-Kil Lim
Journal:  Mol Cells       Date:  2013-03-22       Impact factor: 5.034

Review 7.  A review of osteocyte function and the emerging importance of sclerostin.

Authors:  Jocelyn T Compton; Francis Y Lee
Journal:  J Bone Joint Surg Am       Date:  2014-10-01       Impact factor: 5.284

Review 8.  The Cementocyte-An Osteocyte Relative?

Authors:  N Zhao; B L Foster; L F Bonewald
Journal:  J Dent Res       Date:  2016-03-30       Impact factor: 6.116

Review 9.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

Review 10.  Regulation of Wnt/β-catenin signaling within and from osteocytes.

Authors:  Travis A Burgers; Bart O Williams
Journal:  Bone       Date:  2013-03-05       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.